The use of somatostatin receptor scintigraphy in medical practice provides new opportunities to identify somatostatin receptors-positive tumors and /or lesions.It offers greater specificity over the agents previously used for tumor imaging including gallium-67, gallium-68, thallium-201, technetium 99m-MIBI and flourine-18- labeled deoxyglucose.Better understanding of the biology of receptors expression in normal and diseased states as well as improvement in radiochemical techniques and pharmacology will lead to find-out the radiopharmaceutical of choice.Nowadays, [In-111-DTPA]-Octreotide is the radio-pharmaceutical of choice currently and widely used for somatostatin receptor scintigraphy and treatment. It has a great potential for visualization of somatostatin receptor-positive tumors.The overall sensitivity to localize neuroendocrine tumors is high. In a number of neuroendocrine tumor types, as well as, in Hodgkin's disease, inclusion of somatostatin receptor scintigraphy in the localization or staging procedure may be very rewarding, either in terms of cose-effectiveness, patient management, or quality of life. The value of somatostatin receptor scintigraphy in patients with other tumors, like breast cancer, or in patients with granulomatous disease has to be established.